Item 2.02 Results of Operations and Financial Condition.

On November 16, 2009, RXi Pharmaceuticals Corporation (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2009, a copy of which is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
The information being furnished under this Item 2.02 in this Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of
Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On November 13, 2009, the board of directors (the "Board") of the Company appointed Noah D. Beerman as a Class I director with a term expiring at the 2011 annual meeting of stockholders of the Company, filling a vacancy that was created when Tod Woolf resigned as a member of the Board on November 5, 2009. The appointment of Mr. Beerman as director was made pursuant to the terms of his employment agreement with the Company. Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
99.1 Press Release issued by RXi Pharmaceuticals Corporation on November 16, 2009.

---

Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RXI PHARMACEUTICALS CORPORATION

Date: November 17, 2009 By: /s/ Konstantinos Andrikopoulos Name: Konstantinos Andrikopoulos Title: Vice President, Legal Counsel

---